AtriCure, Inc. (NASDAQ:ATRC) Shares Bought by Wasatch Advisors LP

Wasatch Advisors LP increased its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 38.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 720,677 shares of the medical device company’s stock after purchasing an additional 200,799 shares during the quarter. Wasatch Advisors LP owned 1.49% of AtriCure worth $21,923,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Advisors Capital Management LLC raised its holdings in AtriCure by 0.6% in the 3rd quarter. Advisors Capital Management LLC now owns 57,223 shares of the medical device company’s stock worth $2,506,000 after purchasing an additional 357 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of AtriCure by 2.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,237 shares of the medical device company’s stock valued at $758,000 after acquiring an additional 484 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of AtriCure by 22.9% during the fourth quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock valued at $221,000 after acquiring an additional 1,155 shares during the last quarter. Aigen Investment Management LP raised its holdings in shares of AtriCure by 24.0% during the fourth quarter. Aigen Investment Management LP now owns 7,136 shares of the medical device company’s stock valued at $255,000 after acquiring an additional 1,383 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of AtriCure by 14.7% during the fourth quarter. Mackenzie Financial Corp now owns 12,295 shares of the medical device company’s stock valued at $439,000 after acquiring an additional 1,575 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insider Buying and Selling

In other news, insider Salvatore Privitera purchased 5,000 shares of the stock in a transaction dated Thursday, May 30th. The stock was acquired at an average cost of $22.25 per share, for a total transaction of $111,250.00. Following the completion of the transaction, the insider now directly owns 103,290 shares in the company, valued at approximately $2,298,202.50. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Salvatore Privitera acquired 5,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was acquired at an average price of $22.25 per share, for a total transaction of $111,250.00. Following the purchase, the insider now owns 103,290 shares of the company’s stock, valued at approximately $2,298,202.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $24.09, for a total transaction of $36,135.00. Following the sale, the insider now owns 71,284 shares in the company, valued at $1,717,231.56. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by company insiders.

AtriCure Stock Down 0.5 %

ATRC stock opened at $22.39 on Wednesday. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $59.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 4.00. The business has a 50 day simple moving average of $22.33 and a 200-day simple moving average of $28.75.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $108.90 million during the quarter, compared to analysts’ expectations of $106.86 million. AtriCure had a negative return on equity of 7.85% and a negative net margin of 8.98%. The company’s revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.23) earnings per share. Sell-side analysts anticipate that AtriCure, Inc. will post -0.75 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ATRC. StockNews.com cut AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. Needham & Company LLC reduced their target price on AtriCure from $46.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Oppenheimer raised AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a report on Tuesday, April 23rd. Canaccord Genuity Group reduced their target price on AtriCure from $57.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. dropped their price target on AtriCure from $42.00 to $34.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.78.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.